Panelists: Raoul S. Concepcion, MD, Urology Associates, PC; Steve Dobbs, Urologic Associates of Oklahoma; Bryan A. Mehlhaff, MD, Oregon Urology Institute; Daniel R. Saltzstein, MD, Urology San Antonio Research; Neal D. Shore, MD, Atlantic Urology Clinics
Published Online: Thursday, January 24, 2013
For High-Definition, Click
In this segment, Neal Shore, MD, discusses the best strategies for sequencing and and combination therapies in castration-resistant prostate cancer.
Shore says that, currently, the answers are unknown but with the multitude of investigator-initiated trials going on, the oncology community will soon be able to find combinations and sequencing methods that are not deleterious. Once a patient’s disease is confirmed, Shore believes the most impactful and well tolerated therapies should be introduced, such as sipuleucel-T.
After that, there is no pre-chemotherapy drug that is approved by the FDA, but there are high hopes for abiraterone acetate in that space. Enzalutamide is a similar drug to abiraterone in the space it’s approved in and overall efficacy. Shore believes enzalutamide in the pre-chemotherapy stage is farther off than abiraterone.
Shore admits that there will not be a single combination or sequence that will cure prostate cancer for everyone. The goal for urologists and oncologists is to cause prostate cancer to be considered a controllable, chronic disease. The only path to this endpoint is by way of data.
Peer Exchange Panel:
Raoul S. Concepcion, MD
Editor-in-Chief, Urologists in Cancer Care
Director of Clinical Research
Urology Associates, PC
CEO, Urologic Associates of Oklahoma,
Bryan A. Mehlhaff, MD
Principal Investigator, Division of Clinical Research, Oregon Urology Institute, Springfield, Oregon
Neal D. Shore, MD
Director, CPI, Carolina Urologic Research Center,
Grand Strand Urology/Atlantic Urology Clinics,
Myrtle Beach, South Carolina
Daniel R. Saltzstein, MD
Medical Director, Urology San Antonio Research,
San Antonio, Texas
View More From This Discussion
► Episode 1 Prostate Cancer Management: Introduction and Overview
The content contained in this video is for general information purposes only. The viewer is encouraged to confirm the information presented with other sources. OncLiveTV Peer Exchange makes no representations or warranties of any kind about the completeness, accuracy, timeliness, reliability, or suitability of any of the information, including content or advertisements, contained in this video and expressly disclaims liability for any errors and omissions that may be presented in this video. OncLiveTV Peer Exchange reserves the right to alter or correct any error or omission in the information it provides in this video, without any obligations. OncLiveTV Peer Exchange further disclaims any and all liability for any direct, indirect, consequential, special, exemplary, or other damages arising from the use or misuse of any material or information presented in this video. The views expressed in this video are those of the panelists and do not necessarily reflect the opinion or policy of OncLiveTV Peer Exchange.